To better address this issue, recent findings suggest that the sensitivity of BRAF V600E mutant MM patients to Vemurafenib-treatment can be improved by targeting Glutathione Peroxidase 4 (GPX4) and ferroptosis through the plant sesquiterpene lactones DET and DETD-3 [68]. This evidence concerns the gene GPX4 and Miyoshi myopathy.